What Happens Next for Moderna's and Pfizer's Coronavirus Vaccine Candidates

December will be a crucial month for both Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE). These leaders in the coronavirus vaccine race have reached the final hurdle. Earlier this week, Moderna requested Emergency Use Authorization (EUA) for its coronavirus vaccine candidate. Pfizer and its partner BioNTech (NASDAQ: BNTX) made their request about ten days earlier.

In the meantime, nine other programs remain in phase 3 studies. So even if Moderna and Pfizer cross the finish line with EUAs in their hands, that doesn't mean the race is over. The U.S. Food and Drug Administration (FDA) may grant EUAs to other players in the coming months if their results are solid. Before that, a lot may happen, however. Let's take a look at what's next for the Moderna and Pfizer vaccine candidates.

Image source: Getty Images.

Continue reading

Source Fool.com